Company intelligence / Profile preview
Instil Bio, Inc.
Dallas, Texas, United Statesinstilbio.com ↗
- Ownership
- Public · TIL
- Employees
- ~14
- Development stage
- Phase 2
01
Overview
Instil Bio’s lead program AXN/SYN/IMM2510—a PD-L1xVEGF bispecific antibody—has shown promising safety and efficacy signals in early-phase trials for advanced/metastatic NSCLC and other solid tumors. Initial data from the ongoing first-line chemotherapy combination trial in China are expected as soon as the second half of 2025. The company plans to initiate a U.S. bridging study before end of 2025 with potential global registrational studies to follow.
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodiesTIL cell therapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.—licensing partnership for development/commercialization of bispecific antibodies including AXN/SYN/IMM2510; ImmuneOnco leads Greater China development while Instil retains rights elsewhere.
04
Financials
- Market cap
- $51.4M
- Total revenue
- $0
- Enterprise value
- $-14.6M
Beyond the preview
Go deeper on Instil Bio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Instil Bio, Inc..